Laurus stock reports 29 percent revenue growth in Q1 FY27

Laurus stock is tied to Q1 FY27 revenue of INR 2,026 crore, up 29 percent from INR 1,570 crore a year earlier. The latest operating figures show why contract development and manufacturing organization activity has become central to the investment case.

Revenue growth accelerates

According to StockFin, Laurus Labs generated INR 2,026 crore of revenue in Q1 FY27, compared with INR 1,570 crore in Q1 FY26. That 29 percent increase was accompanied by a rise in operating profit from INR 389 crore to INR 644 crore, a 66 percent gain.

The margin expansion is the more important operating detail. EBITDA margin reached 31.8 percent in Q1 FY27, versus 24.8 percent in the year-earlier quarter, while earnings per share increased to INR 6.81 from INR 3.61.

FY26 sets a larger base

The same StockFin review cites FY26 revenue of INR 6,813 crore and EBITDA of INR 1,826 crore. Revenue grew 23 percent across the FY20 to FY26 period, giving the June-quarter performance a longer operating backdrop rather than treating it as a single-quarter outlier.

Laurus Labs is listed on the NSE under ticker LAURUSLABS, according to MarketWatch. The company operates in the healthcare sector and pharmaceuticals industry, with APIs, finished generic medicines and CDMO services forming the core business mix.

Market value reaches INR 1.1 trillion

Laurus Labs had a market capitalization of INR 1.1 trillion on September 30, 2026. Its primary-exchange quote stood at INR 1,980.00 at 3:15 p.m. IST on that date, against a 52-week range of INR 843.00 to INR 2,055.30.